Symmetry Investments LP Sells 16,300 Shares of Danaher Co. (NYSE:DHR)

Symmetry Investments LP trimmed its position in shares of Danaher Co. (NYSE:DHR) by 53.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,000 shares of the conglomerate’s stock after selling 16,300 shares during the quarter. Symmetry Investments LP’s holdings in Danaher were worth $3,498,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. Gilbert & Cook Inc. grew its stake in shares of Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after purchasing an additional 86 shares during the last quarter. Accretive Wealth Partners LLC boosted its holdings in Danaher by 12.9% in the fourth quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after acquiring an additional 414 shares during the last quarter. Gryphon Financial Partners LLC increased its position in Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after purchasing an additional 468 shares during the period. TrinityPoint Wealth LLC raised its holdings in Danaher by 12.4% during the 4th quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock worth $340,000 after purchasing an additional 162 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its stake in shares of Danaher by 13.6% in the 4th quarter. D.A. Davidson & CO. now owns 13,653 shares of the conglomerate’s stock valued at $3,159,000 after purchasing an additional 1,637 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on DHR. TD Cowen boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Insider Buying and Selling at Danaher

In related news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $272.63 on Friday. The company has a market capitalization of $201.93 billion, a P/E ratio of 46.21, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The company’s 50-day moving average is $267.62 and its 200 day moving average is $257.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 EPS. On average, equities research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.